These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8991188)

  • 1. Liver function tests and lidocaine metabolism (MEGX test) during i.v. CMF therapy in breast cancer.
    Rizzi V; Cioschi B; Cartei G; Bertolissi A; Tabaro G; Marsilio P
    Anticancer Drugs; 1996 Nov; 7(8):846-50. PubMed ID: 8991188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.
    Huang YS; Lee SD; Deng JF; Wu JC; Lu RH; Lin YF; Wang YJ; Lo KJ
    J Hepatol; 1993 Aug; 19(1):140-7. PubMed ID: 8301034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
    Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
    Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
    Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
    Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MEGX test: a tool for the real-time assessment of hepatic function.
    Oellerich M; Armstrong VW
    Ther Drug Monit; 2001 Apr; 23(2):81-92. PubMed ID: 11294522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycinexylidide.
    Oni G; Brown S; Burrus C; Grant L; Watkins J; Kenkel M; Barton F; Kenkel J
    Aesthet Surg J; 2010; 30(6):853-8. PubMed ID: 21131461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoethylglycinexylidide--a metabolite of lidocaine--as an index of liver function in chronic hepatic parenchymal diseases].
    Kupcová V; Turecký L; Szántová M; Schmidtová K
    Bratisl Lek Listy; 1999 Jan; 100(1):12-24. PubMed ID: 10492993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of lidocaine metabolite (monoethylglycinexylidide) as a liver function test].
    Shimanuki K; Suzuki W; Sakurabayashi I; Kiyozaki H; Shinohara K; Soda K; Kai T; Satake M; Miyata M
    Nihon Shokakibyo Gakkai Zasshi; 1993 Jan; 90(1):33-40. PubMed ID: 8433534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients.
    Watanabe T
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S68-70. PubMed ID: 9750032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease.
    Shiffman ML; Luketic VA; Sanyal AJ; Thompson EB
    Ther Drug Monit; 1996 Aug; 18(4):372-7. PubMed ID: 8857553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease.
    Testa R; Caglieris S; Risso D; Arzani L; Campo N; Alvarez S; Giannini E; Lantieri PB; Celle G
    Am J Gastroenterol; 1997 Dec; 92(12):2268-73. PubMed ID: 9399768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
    Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
    J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors.
    Zotz RB; von Schönfeld J; Erhard J; Breuer N; Lange R; Beste M; Goebell H; Eigler FW
    Transplantation; 1997 Feb; 63(4):538-41. PubMed ID: 9047147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.